Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type- Global Industry Analysis, Share, Growth, Regional Outlook And Forecasts, 2021-2027

The global Vaccines market gathered revenue around USD 32,520 Million in 2020 and market is set to grow USD 54,153 Million by the end of 2027 and is estimated to expand at a modest CAGR of 8.1% during the prediction period 2021 to 2027. The growth of this market is majorly attributed to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government support for vaccine development, and the rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Vaccines market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Vaccines market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.

COVID-19 Impact Assessment on Market Landscape

The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.

Vaccines market report empowers readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.

Scope of the Report

This report provides an all-inclusive environment of the analysis for the Vaccines Market. The market estimates provided in the report are the result of in-depth secondary research, primary interviews and in-house expert reviews. These market estimates have been considered by studying the impact of various social, political and economic factors along with the current market dynamics affecting the Vaccines Market growth

Along with the market overview, which comprises of the market dynamics the chapter includes a Porter’s Five Forces analysis which explains the five forces: namely buyers bargaining power, suppliers bargaining power, threat of new entrants, threat of substitutes, and degree of competition in the Vaccines Market. It explains the various participants, such as system integrators, intermediaries and end-users within the ecosystem of the market. The report also focuses on the competitive landscape of the Vaccines Market.

Report Highlights Details
Market Size US$  54,153 Million by 2027
Growth Rate CAGR of  8.1% From 2021 to 2027
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2027
Segments Covered Technology type,Indication,End User
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Companies Mentioned laxoSmithKline plc. (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), and Sanofi Pasteur SA (France). CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), Serum Institute of India (India), AstraZeneca (UK), Bavarian Nordic (Denmark),

Competitive Rivalry

Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

  • Company Overview
  • Company Market Share/Positioning Analysis
  • Product Offerings
  • Financial Performance
  • Recent Initiatives
  • Key Strategies Adopted by Players
  • Vendor Landscape
  • List of Suppliers
  • List of Buyers

Significant Market Participants Operational in the Vaccines Market are:

The global vaccines market are GlaxoSmithKline plc. (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), and Sanofi Pasteur SA (France). Other prominent players in this market include CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), Serum Institute of India (India), AstraZeneca (UK), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan).

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

Market Segments

By Technology type

  • Recombinant & Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others

By Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, & Rubella
  • Diphtheria, Pertussis, & Tetanus {DPT}
  • Polio
  • Hepatitis
  • Other Indications

By End User

  • Pediatric
  • Adults
  • Travelers

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Highlights of the Report:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market

Research Methodology

A unique research methodology has been utilized by Nova one advisor to conduct comprehensive research on the growth of the global Vaccines market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Nova one advisor employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation that looks market from three different perspectives. Critical elements of methodology employed for all our studies include:

Preliminary data mining

Raw market data is obtained and collated on a broad front. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. For comprehensive understanding of the market, it is essential to understand the complete value chain and in order to facilitate this; we collect data from raw material suppliers, distributors as well as buyers.

Technical issues and trends are obtained from surveys, technical symposia and trade journals. Technical data is also gathered from intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered. As a result, the material developed contains a wide range of original data that is then further cross-validated and authenticated with published sources.

Statistical model

Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise.

Econometric models are generally used for short-term forecasting, while technological market models are used for long-term forecasting. These are based on an amalgamation of technology landscape, regulatory frameworks, economic outlook and business principles. A bottom-up approach to market estimation is preferred, with key regional markets analyzed as separate entities and integration of data to obtain global estimates. This is critical for a deep understanding of the industry as well as ensuring minimal errors. Some of the parameters considered for forecasting include:

  • Market drivers and restrains, along with their current and expected impact
  • Raw material scenario and supply v/s price trends
  • Regulatory scenario and expected developments
  • Current capacity and expected capacity additions up to 2027

We assign weights to these parameters and quantify their market impact using weighted average analysis, to derive an expected market growth rate.

Primary validation

This is the final step in estimating and forecasting for our reports. Exhaustive primary interviews are conducted, on face to face as well as over the phone to validate our findings and assumptions used to obtain them. Interviewees are approached from leading companies across the value chain including suppliers, technology providers, domain experts and buyers so as to ensure a holistic and unbiased picture of the market. These interviews are conducted across the globe, with language barriers overcome with the aid of local staff and interpreters. Primary interviews not only help in data validation, but also provide critical insights into the market, current business scenario and future expectations and enhance the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants (KIPs) which typically include:

  • Market leading companies
  • Raw material suppliers
  • Product distributors
  • Buyers

The key objectives of primary research are as follows:

  • To validate our data in terms of accuracy and acceptability
  • To gain an insight in to the current market and future expectations

Secondary Validation

Secondary research sources referred to by analysts during the production of the global Vaccines market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of Nova one advisor’s study on the Vaccines market as primary methods.

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2027);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Vaccines Market, By Technology type

7.1.  Vaccines Market, by Technology type, 2021-2027

7.1.1.     Recombinant & Conjugate Vaccines

7.1.1.1.          Market Revenue and Forecast (2016-2027)

7.1.2.     Inactivated Vaccines

7.1.2.1.          Market Revenue and Forecast (2016-2027)

7.1.3.     Toxoid Vaccines

7.1.3.1.          Market Revenue and Forecast (2016-2027)

7.1.4.     Others

7.1.4.1.          Market Revenue and Forecast (2016-2027)

Chapter 8.    Global Vaccines Market, By Indication

8.1.  Vaccines Market, by Indication, 2021-2027

8.1.1.     Pneumococcal Disease

8.1.1.1.          Market Revenue and Forecast (2016-2027)

8.1.2.     Influenza

8.1.2.1.          Market Revenue and Forecast (2016-2027)

8.1.3.     Human Papilloma Virus

8.1.3.1.          Market Revenue and Forecast (2016-2027)

8.1.4.     Meningococcal Disease

8.1.4.1.          Market Revenue and Forecast (2016-2027)

8.1.5.     Meningococcal Disease

8.1.5.1.          Market Revenue and Forecast (2016-2027)

8.1.6.     Varicella, Measles, Mumps, & Rubella

8.1.6.1.          Market Revenue and Forecast (2016-2027)

8.1.7.     Diphtheria, Pertussis, & Tetanus {DPT}

8.1.7.1.          Market Revenue and Forecast (2016-2027)

8.1.8.     Polio

8.1.8.1.          Market Revenue and Forecast (2016-2027)

8.1.9.     Hepatitis

8.1.9.1.          Market Revenue and Forecast (2016-2027)

8.1.10.  Other Indications

8.1.10.1.       Market Revenue and Forecast (2016-2027)

Chapter 9.    Global Vaccines Market, By End User

9.1.  Vaccines Market, by End User, 2021-2027

9.1.1.     Pediatric

9.1.1.1.          Market Revenue and Forecast (2016-2027)

9.1.2.     Adults

9.1.2.1.          Market Revenue and Forecast (2016-2027)

9.1.3.     Travelers

9.1.3.1.          Market Revenue and Forecast (2016-2027)

Chapter 10.Global Vaccines  Market, Regional Estimates and Trend Forecast

10.1.          North America

10.1.1.  Market Revenue and Forecast, by Technology type (2016-2027)

10.1.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.1.3.  Market Revenue and Forecast, by End User (2016-2027)

10.1.4.  U.S.

10.1.4.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.1.4.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.1.4.3.       Market Revenue and Forecast, by End User (2016-2027)

10.1.5.  Rest of North America

10.1.5.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.1.5.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.1.5.3.       Market Revenue and Forecast, by End User (2016-2027)

10.2.          Europe

10.2.1.  Market Revenue and Forecast, by Technology type (2016-2027)

10.2.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.2.3.  Market Revenue and Forecast, by End User (2016-2027)

10.2.4.  UK

10.2.4.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.2.4.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.2.4.3.       Market Revenue and Forecast, by End User (2016-2027)

10.2.5.  Germany

10.2.5.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.2.5.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.2.5.3.       Market Revenue and Forecast, by End User (2016-2027)

10.2.6.  France

10.2.6.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.2.6.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.2.6.3.       Market Revenue and Forecast, by End User (2016-2027)

10.2.7.  Rest of Europe

10.2.7.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.2.7.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.2.7.3.       Market Revenue and Forecast, by End User (2016-2027)

10.3.          APAC

10.3.1.  Market Revenue and Forecast, by Technology type (2016-2027)

10.3.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.3.3.  Market Revenue and Forecast, by End User (2016-2027)

10.3.4.  India

10.3.4.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.3.4.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.3.4.3.       Market Revenue and Forecast, by End User (2016-2027)

10.3.5.  China

10.3.5.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.3.5.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.3.5.3.       Market Revenue and Forecast, by End User (2016-2027)

10.3.6.  Japan

10.3.6.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.3.6.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.3.6.3.       Market Revenue and Forecast, by End User (2016-2027)

10.3.7.  Rest of APAC

10.3.7.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.3.7.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.3.7.3.       Market Revenue and Forecast, by End User (2016-2027)

10.4.          MEA

10.4.1.  Market Revenue and Forecast, by Technology type (2016-2027)

10.4.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.4.3.  Market Revenue and Forecast, by End User (2016-2027)

10.4.4.  GCC

10.4.4.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.4.4.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.4.4.3.       Market Revenue and Forecast, by End User (2016-2027)

10.4.5.  North Africa

10.4.5.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.4.5.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.4.5.3.       Market Revenue and Forecast, by End User (2016-2027)

10.4.6.  South Africa

10.4.6.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.4.6.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.4.6.3.       Market Revenue and Forecast, by End User (2016-2027)

10.4.7.  Rest of MEA

10.4.7.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.4.7.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.4.7.3.       Market Revenue and Forecast, by End User (2016-2027)

10.5.          Latin America

10.5.1.  Market Revenue and Forecast, by Technology type (2016-2027)

10.5.2.  Market Revenue and Forecast, by Indication (2016-2027)

10.5.3.  Market Revenue and Forecast, by End User (2016-2027)

10.5.4.  Brazil

10.5.4.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.5.4.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.5.4.3.       Market Revenue and Forecast, by End User (2016-2027)

10.5.5.  Rest of LATAM

10.5.5.1.       Market Revenue and Forecast, by Technology type (2016-2027)

10.5.5.2.       Market Revenue and Forecast, by Indication (2016-2027)

10.5.5.3.       Market Revenue and Forecast, by End User (2016-2027)

Chapter 11.   Company Profiles

11.1.                 laxoSmithKline plc.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.                 Pfizer, Inc.

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.                 Merck & Co., Inc.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.                 Sanofi Pasteur SA

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.                 CSL Limited

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.                 CSL Limited

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.                 Johnson & Johnson

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.                 Serum Institute of India

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.                 AstraZeneca

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.              Bavarian Nordic

11.10.1.                   Company Overview

11.10.2.                   Product Offerings

11.10.3.                   Financial Performance

11.10.4.                   Recent Initiatives

Chapter 12.   Research Methodology

12.1.                 Primary Research

12.2.                 Secondary Research

12.3.                 Assumptions

Chapter 13.   Appendix

13.1.                 About Us

13.2.                 Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers